Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBT124 biosimilar bevacizumab versus EU-sourced Avastin in first-line non-squamous NSCLC
2016-003301-34Phase 3Completed
- Sponsor
- Cipla BioTec
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing CBT124 + carboplatin + paclitaxel with Avastin + carboplatin + paclitaxel (2 arms). Primary endpoint: Objective Response Rate. Started Oct 2016; status: completed.
02
Drugs
bevacizumab biosimilar (CBT124)bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2016-003301-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003301-34.